An interventional study of Oliceridine and Oxycodone in Vitrectomy, sponsored by Henan Provincial People's Hospital. Not yet recruiting. Open to participants aged 18 Years to 75 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-07-31.
Sponsored by Henan Provincial People's Hospital · Not applicable, Interventional, and Prevention
Traditional opioid analgesia is a method to treat moderate to severe pain. However, the use of opioids is not without risks. When treating acute pain, patients may have hypotension, respiratory depression, hypoxia, nausea and vomiting, irritability and pruritus. The aim of this study was to evaluate the analgesic effect and safety of g-protein-biased μ - opioid receptor agonists Oliceridine and oxycodone in vitrectomy.
a total of 120 patients scheduled for vitrectomy were randomly divided into Oliceridine group (n = 60) and oxycodone group (n = 60). The main outcome measure was visual analogue scale (VAS) at 2 hours after operation, and the secondary outcome measures included intraoperative analgesic drug addition, VAS scores at 6 and 24 hours after operation, respiratory depression (oxygen saturation \< 90%) and incidence of adverse reactions (nausea, vomiting, dizziness).
Henan Provincial People's Hospital is the lead sponsor of 63 studies on the registry; 33 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Intraoperative analgesia: Oliceridine 0.015mg/kg
Drug: Oliceridine
Intraoperative analgesia oxycodone 0.04mg/kg
Drug: Oxycodone
Intraoperative analgesia should be administered with Oliceridine
Oxycodone is used for intraoperative analgesia
VAS score 2 hours after operation
Postoperative 2-hour VAS score (total score of 10, 0 indicates no pain, and 10 indicates the most severe unbearable pain)
Time frame: From enrollment to the end of treatment at 1 day
Adverse reactions
ncidence of nausea, vomiting, dizziness, headache, constipation, itching, and hypoxia
Time frame: From enrollment to the end of treatment at 1 day
No study locations are listed for this record.
Plan to share: No
No publications or documents are linked to this record.
This study is not yet recruiting, as verified in Jul 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Henan Provincial People's Hospital